title: Metabolon, Inc.
abstract: Metabolon is an emerging technology company developing proprietary analytical methods and software for biomarker discovery using metabolomics. The company's aim is to measure all small molecules (<1500 Da) in a biological sample. These small-molecule compounds include biochemicals of cellular metabolism and xenobiotics from diet and environment. Our proprietary mLIMStrade mark system contains advanced metabolomic software and automated data-processing tools that use a variety of data-analysis and quality-control algorithms to convert raw mass-spectrometry data to identified, quantitated compounds. Metabolon's primary focus is a fee-for-service business that exploits this technology for pharmaceutical and biotechnology companies, with additional clients in the consumer goods, cosmetics and agricultural industries. Fee-for-service studies are often collaborations with groups that employ a variety of technologies for biomarker discovery. Metabolon's goal is to develop technology that will automatically analyze any sample for the small-molecule components present and become a standard technology for applications in health and related sciences.
authors.affiliation: Metabolon, Inc., 800 Capitola Drive, Suite 1, Durham, NC 27713, USA.
authors.forename: John
authors.initials: J
authors.lastname: Ryals
authors.forename: Kay
authors.initials: K
authors.lastname: Lawton
authors.forename: Daniel
authors.initials: D
authors.lastname: Stevens
authors.forename: Michael
authors.initials: M
authors.lastname: Milburn
mesh_terms: D004358:Drug Therapy / Q000379:methods; D005819:Genetic Markers / Q000235:genetics; D006801:Humans; D008660:Metabolism; D010597:Pharmacogenetics / Q000379:methods*; D013672:Technology / Q000639:trends
chemical_list: D005819:Genetic Markers